Ionis Q3: Revenue $242.7M, Net Loss $110.0M; TRYNGOLZA Guidance Cut and Pelacarsen Royalty Write-Down
IONS is trading near its 52-week low of $38.305 (18% below the low).
Summary
Ionis posted Q3 revenue of $242.7M and a $110.0M net loss, with DAWNZERA offsetting a sharp TRYNGOLZA decline; the 10-Q also details a pelacarsen-driven royalty liability re-estimate and two Roche collaboration terminations.
Key Events · Earnings and Guidance · IONS
-
Q3 Revenue Up 55%, Loss Narrows Sequentially
Total revenue was $242.7M versus $156.7M a year earlier; net loss was $110.0M, or $0.66 per share, versus $128.6M a year earlier.
-
TRYNGOLZA Sales Collapse, DAWNZERA Carries Quarter
TRYNGOLZA net sales fell to $9.3M from $31.8M a year earlier, while DAWNZERA rose to $36.8M from $0.7M and new ZANVASTRO contributed $2.2M.
-
Pelacarsen Failure Resets Royalty Liability
After the Phase 3 miss, Ionis set expected pelacarsen royalties to zero and raised the SPINRAZA royalty cap payable to Royalty Pharma from $475M to $550M, moving the arrangement into contra-interest expense.
-
Roche Terminates Two Collaborations
Roche terminated the Alzheimer's/Huntington's RNA program collaboration effective November 2026 and the separate Huntington's collaboration effective October 2026.
Analysis · IONS · Life Sciences
Revenue grew 55% to $242.7M in Q3, but the quality of that growth is mixed: DAWNZERA carried the quarter at $36.8M while TRYNGOLZA sales collapsed to $9.3M from $31.8M a year earlier, consistent with the guidance cut already flagged in this morning's 8-K. The 10-Q adds two items the headline release did not fully spell out. First, the pelacarsen Phase 3 failure forced Ionis to zero out expected pelacarsen royalties and raise the SPINRAZA royalty cap payable to Royalty Pharma from $475M to $550M, which flips the royalty financing into contra-interest expense going forward. Second, Roche terminated two collaborations (Alzheimer's/Huntington's programs), removing partnered pipeline optionality. With $1.9B of cash and investments and a $317.1M nine-month net loss, funding is not an immediate issue, but the widening loss and rising SG&A ($154.2M vs $96.8M) show the launch build-out is expensive while the newest launch underperforms.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IONS was trading at $31.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $38.31 to $86.74. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.